March 27, 2020 07:26 AM EDTUpdated March 30, 04:11 AM
R&D
Cell/Gene Tx

VBL and its 'gene ther­a­py' can­cer treat­ment are back — with a peek at PhI­II po­ten­tial

Jason Mast

Editor

Three years af­ter a brain can­cer fail­ure sent the com­pa­ny reel­ing, VBL Ther­a­peu­tics is tout­ing its first hint of pos­i­tive Phase III re­sults.

The Is­raeli …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times